Top 10 Daridorexant (Quviviq) Generic Manufacturers in Australia
The pharmaceutical landscape in Australia is evolving rapidly, particularly in the area of generics. The Australian generic medicines market has seen significant growth, with a reported market size of approximately AUD 2.2 billion in 2022, accounting for nearly 50% of all prescription medicines dispensed. A pivotal player in this market is Daridorexant (Quviviq), a dual orexin receptor antagonist approved for the treatment of insomnia. With the increasing prevalence of sleep disorders, the demand for effective generics like Daridorexant is on the rise. This report highlights the top 10 manufacturers of Daridorexant generics in Australia, shedding light on their market positions and contributions.
1. Apotex Pty Ltd
Apotex is one of the largest generic pharmaceutical companies in Australia, with a production capacity exceeding 18 billion tablets annually. The company has a strong portfolio in CNS disorders, including Daridorexant, which has contributed to a significant market share in the generic segment.
2. Mylan Australia
Mylan, now part of Viatris, has a robust presence in the Australian market, producing over 300 generic medicines. Their focus on quality and affordability has made them a leader in the sleep disorder therapy market, capturing around 15% of the Australian generics market.
3. Sandoz Australia
Sandoz, a Novartis division, specializes in generic pharmaceuticals and biosimilars. They have a significant share of the market, estimated at 12%, and are known for their consistent supply of high-quality generics, including Daridorexant, which supports their position in the insomnia treatment landscape.
4. Sigma Healthcare
Sigma Healthcare is a key player in the Australian pharmaceutical distribution and manufacturing sector. With an impressive annual production rate of over 1 billion units, Sigma’s generics division has been critical in addressing the growing demand for Daridorexant, enhancing their market reach.
5. Generic Health
Generic Health focuses exclusively on the production of generic medicines. They have a strong reputation in the industry, with a market share of around 5%. Their commitment to quality control and innovation in the production of Daridorexant has positioned them as a reliable supplier in Australia.
6. Bristol-Myers Squibb
While primarily a brand-name pharmaceutical company, Bristol-Myers Squibb has also ventured into generics through strategic partnerships. Their generics division has been instrumental in distributing Daridorexant, leveraging their extensive distribution networks to reach a wider audience.
7. Cipla Australia
Cipla is a global pharmaceutical company with a growing footprint in Australia. They manufacture a diverse range of generics, including Daridorexant, with a production volume exceeding 500 million units per year. Cipla’s commitment to affordability has strengthened their market presence.
8. Hetero Labs Limited
Hetero is known for its extensive range of affordable generics worldwide. In Australia, they have made significant inroads into the market for Daridorexant, leveraging their production capabilities that exceed 1 billion units annually, focusing on advanced drug formulations.
9. Teva Pharmaceuticals Australia
Teva is a global leader in generic pharmaceuticals and has a strong foothold in the Australian market. Their extensive portfolio includes Daridorexant, which has contributed to an annual revenue of AUD 1 billion in the generics sector, ensuring a steady supply for Australian patients.
10. Fresenius Kabi
Fresenius Kabi specializes in generic and specialty pharmaceuticals, with a focus on injectable drugs. Their entry into the Daridorexant market has been marked by innovative delivery methods and a commitment to quality, enhancing their competitive edge in the generics space.
Insights
The market for Daridorexant generics in Australia is projected to grow substantially, with an estimated compound annual growth rate (CAGR) of 8% over the next five years, driven by increasing awareness of sleep disorders and the need for effective treatments. The total market size for insomnia medications is expected to reach AUD 400 million by 2027. As healthcare costs continue to rise, the demand for affordable generics is likely to increase, positioning manufacturers who prioritize quality and accessibility for growth opportunities in this evolving landscape. The competitive dynamics among the top manufacturers will play a crucial role in shaping the availability and affordability of Daridorexant in the Australian market.
Related Analysis: View Previous Industry Report
